Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Disulfiram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 known ✓ | P05091 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | MGLL | Q99685 | 7/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 1.00 |
| ▸ | PHGDH | O43175 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | GSDMD | P57764 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | FBP1 | P09467 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | LOX | P28300 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Disulfiram SCHEMBL27213 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL11155542 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL28074264 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL5364281 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL10886601 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL31719635 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL28246322 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL5961375 | 0.97 | ALDH1A1 (0.94) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL4734237 | 0.94 | ALDH1A1 (0.89) | ALDH1A1ALDH2MGLLEHMT2EHMT1 | |
| Disulfiram SCHEMBL10542872 | 0.94 | ALDH1A1 (0.89) | ALDH1A1ALDH2MGLLEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786490-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2023-10-17 | — | — | US | disclosed |
| US-11773238-B2 | Accelerator for the vulcanization of rubbery polymers | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11685712-B2 | Synthesis of monofunctional thiuram accelerator | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230029068-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | THE GOODYEAR TIRE & RUBBER COMPANY | 2023-01-26 | — | — | US | disclosed |
| CN-113121395-A | Synthesis of monofunctional thiuram accelerators | 固特异轮胎和橡胶公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3845520-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | The Goodyear Tire & Rubber Company (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210198194-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | THE GOODYEAR TIRE & RUBBER COMPANY | 2021-07-01 | — | — | US | disclosed |
| US-20210161835-A1 | Combination Treatments for Opioid Crisis | PRESTI MICHAEL (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2021015300-A1 | AGENT FOR TREATING, PREVENTING OR IMPROVING PSYCHIATRIC AND NERVOUS SYSTEM DISORDERS OR SYMPTOMS | 学校法人東京理科大学 | 2021-01-28 | — | — | WO | disclosed |
| WO-2020054821-A1 | DISULFIRAM-CONTAINING ACTIVITY INHIBITOR FOR GROUP 2 INNATE LYMPHOID CELL (ILC2) | 学校法人慶應義塾 | 2020-03-19 | — | — | WO | disclosed |
| US-20050096304-A1 | Method of treating cancer using dithiocarbamate derivatives | WATER STREET HEALTHCARE PARTNERS II L.P. | 2005-05-05 | — | — | US | disclosed |
| WO-2005009338-A2 | METHOD OF INHIBITING ATF/CREB AND CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITIONS FOR SAME | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A/ CAROLINAS MEDICAL CENTER (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040171678-A1 | Method of treating cancer using dithiocarbamate derivatives | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2004-09-02 | — | — | US | disclosed |
| US-6706759-B1 | SENSITIZING TUMORS TO CONVENTIONAL CANCER CHEMOTHERAPY BY BLOCKING THE P-GLYCOPROTEIN MEMBRANE TOXIN EXTRUSION PUMP AND FOR SENSITIZING AIDS PATIENTS TO ANTI-RETROVIRAL THERAPY BY BLOCKING THE P-GLYCOPROTEIN MEMBRANE TOXIN EXTRUSION PUMP | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY | 2004-03-16 | — | — | US | disclosed |
| US-20040019102-A1 | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2004-01-29 | — | — | US | disclosed |
| US-20030229064-A1 | Method of treating cancer using dithiocarbamate derivatives | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER | 2003-12-11 | — | — | US | disclosed |
| EP-1328267-A2 | METHOD OF TREATING CANCER USING DITHIOCARBAMATE DERIVATIVES | Charlotte-Mecklenburg Hospital Authority doing business as Carolinas Medical Center (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6548540-B2 | Administering dithiocarbamate thiolate anions to sensitize humans to conventional chemotherapy by blocking the p-glycoprotein membrane toxin extrusion pump | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY | 2003-04-15 | — | — | US | disclosed |
| WO-2002028349-A2 | METHOD OF TREATING CANCER USING DITHIOCARBAMATE DERIVATIVES | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY, DOING BUSINESS AS CAROLINAS MEDICAL CENTER (US) | 2002-04-11 | — | — | WO | disclosed |
| US-20010016600-A1 | Method of treating cancer using dithiocarbamate derivatives | THE UNIVERSITY OF UTAH | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096304-A1 | Method of treating cancer using dithiocarbamate derivatives | SLC47A1, SLC47A2, ABCC1 | ALDH2 920/4885ALDH1A1 2489/4885MGLL 2686/4885 |
| US-20030229064-A1 | Method of treating cancer using dithiocarbamate derivatives | TST, HCCS, SERPINC1 | ALDH2 263/4885ALDH1A1 1338/4885MGLL 4162/4885 |
| US-20010016600-A1 | Method of treating cancer using dithiocarbamate derivatives | TST, HCCS, SERPINC1 | ALDH2 263/4885ALDH1A1 1338/4885MGLL 4162/4885 |
| US-20230029068-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | TST, TERT, MGMT | ALDH2 632/4885ALDH1A1 868/4885MGLL 2630/4885 |
| US-20040171678-A1 | Method of treating cancer using dithiocarbamate derivatives | TST, HCCS, SERPINC1 | ALDH2 263/4885ALDH1A1 1338/4885MGLL 4162/4885 |
| US-20040019102-A1 | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same | ATF4, ATF1, CREBBP | ALDH2 48/4885ALDH1A1 92/4885MGLL 2681/4885 |
| US-11685712-B2 | Synthesis of monofunctional thiuram accelerator | TST, TERT, MGMT | ALDH2 632/4885ALDH1A1 868/4885MGLL 2630/4885 |
| US-20210198194-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | TST, TERT, MGMT | ALDH2 632/4885ALDH1A1 868/4885MGLL 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.